Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
165,547,872
-
Total 13F shares
-
37,729,759
-
Share change
-
+3,282,573
-
Total reported value
-
$314,277,192
-
Price per share
-
$8.33
-
Number of holders
-
130
-
Value change
-
+$28,164,183
-
Number of buys
-
79
-
Number of sells
-
44
Institutional Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2020
As of 30 Jun 2020,
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) was held by
130 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
37,729,759 shares.
The largest 10 holders included
BlackRock Inc., BVF INC/IL, VANGUARD GROUP INC, PERCEPTIVE ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, VICTORY CAPITAL MANAGEMENT INC, STATE STREET CORP, RTW INVESTMENTS, LP, GREAT POINT PARTNERS LLC, and Point72 Asset Management, L.P..
This page lists
130
institutional shareholders reporting positions in this security
for the Q2 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.